Nephrotic syndrome is a kidney disorder characterized by heavy proteinuria, hypoalbuminemia, edema, and hyperlipidemia. It results from damage to the glomeruli, leading to increased permeability and loss of protein in the urine.1 Common causes include minimal change disease, focal segmental glomerulosclerosis, and membranous nephropathy. Recent advances in treatment focus on corticosteroids, immunosuppressive agents, and newer therapies like calcineurin inhibitors and monoclonal antibodies. Early diagnosis and management are crucial to preventing complications such as infection, thrombosis, and progressive kidney failure. Regular monitoring of proteinuria, kidney function, and lipid levels is essential for effective management.2 Advances in genetic research and biomarkers hold promise for personalized treatment, improving outcomes and reducing the long-term impact of nephrotic syndrome on kidney health.